Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
AACR
American Association for Cancer Research (AACR)
June 1, 2022
,
de Souza, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy.
SITC
Society for Immunotherapy of Cancer (SITC)
June 1, 2022
,
O'Day, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies.
ASCO
American Society of Clinical Oncology (ASCO)
June 1, 2022
,
O'Day, et al.
No items found.